The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in
patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose,
glycated hemoglobin (A1C), and fructosamine were observed. It is unknown whether this
improvement is due to an improvement in insulin sensitivity and insulin secretion. The
purpose of this study is to evaluate the effect of the administration of Momordica Charantia
on insulin sensitivity and insulin secretion in patients with type 2 diabetes mellitus.